文献速递眼底病与葡萄膜炎

啮齿类视网膜脱离模型中光感受器神经保护剂的系统评价

Neuroprotective Agents for Photoreceptor Rescue Following Experimental Retinal Detachment in Rodents: A Systematic Review.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

仅6项研究报告ERG定量数据,多数研究偏倚风险不明确。

要点

  • 抗炎干预TUNEL减少中位84.5%,数值上优于其他机制类别但组间差异无统计学意义。
  • 仅6项研究(16.7%)提供定量ERG数据,功能学证据有限。

核心结论

  • 在啮齿类视网膜脱离模型中,靶向炎症的干预在数值上显示最一致的光感受器保护效果。
  • 不同机制类别间的TUNEL减少差异无统计学意义(Kruskal-Wallis P=0.32)。

研究设计与样本

  • 纳入研究包括19项大鼠、12项小鼠和5项混合物种研究;干预类型包括小分子和重组蛋白(n=30)、单克隆抗体(n=3)、肽(n=2)和细胞外囊泡治疗(n=1)。
  • 主要结局为视网膜组织切片上TUNEL阳性细胞减少(基于组织学),次要结局为外核层(ONL)保留和视网膜电图(ERG)。
  • 使用SYRCLE工具评估偏倚风险。

主要发现

  • 抗炎干预的TUNEL减少中位数为84.5%(IQR=62.3%-88.1%)。
  • 抗炎/抗氧化干预的TUNEL减少中位数为70.8%(IQR=54.3%-76.0%)。
  • 代谢调节剂的TUNEL减少中位数为59.6%(IQR=42.9%-64.8%)。
  • 抗凋亡剂的TUNEL减少中位数为59.0%(IQR=56.6%-69.3%)。
  • 仅6项研究(16.7%)提供定量ERG数据;评估者盲法在63.9%的研究中为低风险。

关键数值与推荐

  • 抗炎干预TUNEL减少中位数84.5%(IQR=62.3%-88.1%)。
  • 抗炎/抗氧化干预TUNEL减少中位数70.8%(IQR=54.3%-76.0%)。
  • 代谢调节剂TUNEL减少中位数59.6%(IQR=42.9%-64.8%)。
  • 抗凋亡剂TUNEL减少中位数59.0%(IQR=56.6%-69.3%)。
  • 组间差异Kruskal-Wallis P=0.32。

临床怎么用

  • 炎症靶向治疗在啮齿类视网膜脱离模型中显示最一致的数值性光感受器保护,可供后续转化研究参考。
  • 8项研究评估FDA已批准的非视网膜适应证药物,提示药物重定位是潜在方向。
  • 需开展严格设计、以功能学为导向且反映临床现实治疗延迟的临床前试验以缩小转化差距。

局限性

  • 仅6项研究(16.7%)提供定量ERG数据,功能学证据有限。
  • 选择和实施领域的偏倚风险大多不明确。
  • 研究间不同机制类别的TUNEL减少差异无统计学意义(P=0.32)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to systematically evaluate neuroprotective interventions for photoreceptor preservation in rodent models of retinal detachment (RD). METHODS: A systematic search of PubMed, Embase, Web of Science, and Google Scholar identified studies evaluating neuroprotective agents in rodent RD models. The primary outcome was a reduction in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells quantified on retinal tissue sections (histology-based); secondary outcomes included preservation of the outer nuclear layer (ONL) and electroretinography (ERG). Risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. RESULTS: Thirty-six studies (2007-2025) met inclusion criteria: 19 rat, 12 mouse, and 5 combined-species. Interventions included small molecules and recombinant proteins (n = 30), monoclonal antibodies (n = 3), peptides (n = 2), and extracellular vesicle therapy (n = 1). Eight (22.2%) evaluated US Food and Drug Administration (FDA)-approved agents for non-retinal indications. Anti-inflammatory interventions achieved the highest median TUNEL reduction (84.5%, interquartile range [IQR] = 62.3%-88.1%), followed by anti-inflammatory/antioxidant approaches (70.8%, IQR = 54.3%-76.0%), metabolic modulators (59.6%, IQR = 42.9%-64.8%), and anti-apoptotic agents (59.0%, IQR = 56.6%-69.3%). Between-group differences were not statistically significant (Kruskal-Wallis P = 0.32). Quantitative ERG data were available in only six studies (16.7%). The risk of bias was largely unclear across selection and performance domains, with assessor blinding most reported (63.9% low risk). Ten studies additionally evaluated genetically modified backgrounds as complementary mechanistic strata (n = 11 experiments). CONCLUSIONS: Inflammation-targeted therapies showed the most consistent numerical photoreceptor rescue across rodent RD studies. With eight studies evaluating FDA-approved agents, the field has clear repurposing opportunities; closing the translational gap will require rigorously designed, functionally oriented preclinical trials that reflect clinically realistic treatment delays.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Baroutis KG, Baroutis D, Ploumi I, et al. Neuroprotective Agents for Photoreceptor Rescue Following Experimental Retinal Detachment in Rodents: A Systematic Review. Invest Ophthalmol Vis Sci. 2026. PMID: 42300676. doi:10.1167/iovs.67.6.28

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。